@article{pmid40239126,

title = {The Complex Journey of Women in Perinatal Psychiatric Care: Susceptibility to Illness Onset, Comorbidity and Clinical Trajectories: Le parcours complexe des femmes en psychiatrie périnatale : vulnérabilité, comorbidités et trajectoires cliniques},

author = {Alexandra Painchaud and Marie-Josée Poulin and Célia Matte-Gagné and Chantal Mérette},

doi = {10.1177/07067437251328347},

issn = {1497-0015},

year  = {2025},

date = {2025-06-01},

journal = {Can J Psychiatry},

volume = {70},

number = {6},

pages = {499--510},

abstract = {BackgroundMore than one in five women deal with a psychiatric disorder during the perinatal period. Whereas perinatal depression is well documented, there is still little research on the full range of perinatal psychiatric disorders and their clinical evolution across this whole period. The present study investigated the susceptibility to psychiatric illness during pregnancy and up to one year postpartum. We aimed to identify the most frequent disorders and comorbidities arising in each perinatal period. We outlined the clinical trajectories of these disorders in terms of evolution across past history, pregnancy and postpartum.MethodThrough a retrospective longitudinal design, data were collected in 2019-2020 from the medical records of the cohort of 964 women who required care in a tertiary perinatal psychiatry clinic located in Quebec City (Canada) between 2004 and 2020. Incidence rates of the full range of psychiatric disorders were estimated per period and their evolution across time identified clinical trajectories.ResultsDuring pregnancy, 34 different disorders were newly diagnosed with incidence rates ranging from 0.1% to 15.5% (45.6% of women having had at least one disorder diagnosed during pregnancy) whereas, during postpartum, 36 disorders were newly diagnosed with incidence rates ranging from 0.1% to 31.0% (67.5% of women having had at least one disorder diagnosed during postpartum). For most disorders, rates were significantly higher in postpartum than in pregnancy. A woman could develop multiple disorders during a given perinatal period: this comorbidity involved various combinations of diagnoses in 28% of women during pregnancy and 38% during postpartum. We outlined 52 different clinical trajectories from past history to postpartum, underlining the heterogeneity of the perinatal course.ConclusionsPregnancy is a susceptible period for women with past psychiatric histories whereas postpartum could trigger a new illness in women without a past history or pregnancy-onset psychiatric disorder.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid35711159,

title = {Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder},

author = {Smadar V Tourjman and Gabriella Buck and Didier Jutras-Aswad and Atul Khullar and Shane McInerney and Gayatri Saraf and Jairo V Pinto and Stephane Potvin and Marie-Josée Poulin and Benicio N Frey and Sidney H Kennedy and Raymond W Lam and Glenda MacQueen and Roumen Milev and Sagar V Parikh and Arun Ravindran and Roger S McIntyre and Ayal Schaffer and Valerie H Taylor and Michael van Ameringen and Lakshmi N Yatham and Serge Beaulieu},

doi = {10.1177/07067437221099769},

issn = {1497-0015},

year  = {2023},

date = {2023-05-01},

journal = {Can J Psychiatry},

volume = {68},

number = {5},

pages = {299--311},

abstract = {BACKGROUND: Given the increasing acceptability and legalization of cannabis in some jurisdictions, clinicians need to improve their understanding of the effect of cannabis use on mood disorders.nnOBJECTIVE: The purpose of this task force report is to examine the association between cannabis use and incidence, presentation, course and treatment of bipolar disorder and major depressive disorder, and the treatment of comorbid cannabis use disorder.nnMETHODS: We conducted a systematic literature review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching PubMed, Embase, PsycINFO, CINAHL and Cochrane Central Register of Controlled Trials from inception to October 2020 focusing on cannabis use and bipolar disorder or major depressive disorder, and treatment of comorbid cannabis use disorder. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to evaluate the quality of evidence and clinical considerations were integrated to generate Canadian Network for Mood and Anxiety Treatments recommendations.nnRESULTS: Of 12,691 publications, 56 met the criteria: 23 on bipolar disorder, 21 on major depressive disorder, 11 on both diagnoses and 1 on treatment of comorbid cannabis use disorder and major depressive disorder. Of 2,479,640 participants, 12,502 were comparison participants, 73,891 had bipolar disorder and 408,223 major depressive disorder without cannabis use. Of those with cannabis use, 2,761 had bipolar disorder and 5,044 major depressive disorder. The lifetime prevalence of cannabis use was 52%-71% and 6%-50% in bipolar disorder and major depressive disorder, respectively. Cannabis use was associated with worsening course and symptoms of both mood disorders, with more consistent associations in bipolar disorder than major depressive disorder: increased severity of depressive, manic and psychotic symptoms in bipolar disorder and depressive symptoms in major depressive disorder. Cannabis use was associated with increased suicidality and decreased functioning in both bipolar disorder and major depressive disorder. Treatment of comorbid cannabis use disorder and major depressive disorder did not show significant results.nnCONCLUSION: The data indicate that cannabis use is associated with worsened course and functioning of bipolar disorder and major depressive disorder. Future studies should include more accurate determinations of type, amount and frequency of cannabis use and select comparison groups which allow to control for underlying common factors.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid33327576,

title = {Creating a Multisite Perinatal Psychiatry Databank: Purpose and Development},

author = {Wid Kattan and Laura Avigan and Barbara Hayton and Jennifer L Barkin and Martin St-André and Tuong-Vi Nguyen and Hannah Schwartz and Marie-Josée Poulin and Irena Stikarovska and Rahel Wolde-Giorghis and Maria Arafah and Phyllis Zelkowitz},

doi = {10.3390/ijerph17249352},

issn = {1660-4601},

year  = {2020},

date = {2020-12-01},

journal = {Int J Environ Res Public Health},

volume = {17},

number = {24},

abstract = {Mental health issues during the perinatal period are common; up to 29% of pregnant and 15% of postpartum women meet psychiatric diagnostic criteria. Despite its ubiquity, little is known about the longitudinal trajectories of perinatal psychiatric illness. This paper describes a collaboration among six perinatal mental health services in Quebec, Canada, to create an electronic databank that captures longitudinal patient data over the course of the perinatal period. The collaborating sites met to identify research interests and to select a standardized set of variables to be collected during clinical appointments. Procedures were implemented for creating a databank that serves both research and clinical purposes. The resulting databank allows pregnant and postpartum patients to complete self-report questionnaires on medical and psychosocial variables during their intake appointment in conjunction with their clinicians who fill in relevant medical information. All participants are followed until 6 months postpartum. The databank represents an opportunity to examine illness trajectories and to study rare mental disorders and the relationship between biological and psychosocial variables.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}